Cargando…
The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era
Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors. Molecular monitoring represents the most sensitive tool to judge chronic myeloid leuk...
Autores principales: | Renault, Ilana Zalcberg, Scholl, Vanesa, Hassan, Rocio, Capelleti, Paola, de Lima, Marcos, Cortes, Jorge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Hematologia e Hemoterapia
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459378/ https://www.ncbi.nlm.nih.gov/pubmed/23049363 http://dx.doi.org/10.5581/1516-8484.20110122 |
Ejemplares similares
-
Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?
por: Bonecker, Simone, et al.
Publicado: (2015) -
Familial Myelodysplastic/Acute Leukemia Syndromes—Myeloid Neoplasms with Germline Predisposition
por: Baptista, Renata Lyrio Rafael, et al.
Publicado: (2017) -
Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011) -
Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review
por: Castillo, Dan Ran, et al.
Publicado: (2022) -
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
por: Kockerols, Camille C.B., et al.
Publicado: (2022)